[2021 ASH] APG-2575, a selective inhibitor of Bcl-2, was selected for two studies, and the Chinese clinical study showed CR

Suzhou, China and Rockville, Maryland, U.

product

Summary

serial number

form

Orebatinib (HQP1351)

Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)

The new third-generation BCR-ABL tyrosine kinase inhibitor (TKI) oribatinib (HQP1351) is the latest in the safety and effectiveness of the Phase I study of TKI-resistant chronic myelogenous leukemia (CML) subjects result

311

Oral report

Oral Presentation

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Orebatinib (HQP1351) is critical for the treatment of tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1T315I mutant chronic myelogenous leukemia in chronic and accelerated phase (CML-CP and CML-AP) subjects Latest results of phase II trials

3598

Poster display

Poster Presentation

Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetic (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Research progress: The pharmacokinetics (PK), safety and effectiveness of oral aoribatinib (HQP1351) in the treatment of refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) 1b bridging study

2551

Poster display

Poster Presentation

Lisaftoclax (APG-2575)

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R /R) Hematologic Malignancies (HMs)

Phase I clinical study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the new BCL-2 inhibitor lisaftoclax (APG-2575) in the treatment of hematological tumors (HMs)

3730

Poster display

Poster Presentation

Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL)

Phase Ib clinical study of lisaftoclax (APG-2575) as a single agent or in combination in the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL)

1554

Poster display

Poster Presentation

Pelcitoclax (APG-1252)

Antitumor Activity of Dual BCL-2/BCL-xl Inhibitor Pelcitoclax (APG-1252) in Natural Killer/T-Cell Lymphoma (NK/TCL)

Anti-natural killer/T cell lymphoma (NK/TCL) activity of BCL-2/BCL-xL dual target inhibitor pelcitoclax (APG-1252)

2062

Poster Presentation

It is worth noting that the data from the multi-center, open-label phase I single-agent study of APG-2575 in the treatment of hematological tumors shows that APG-2575 is well tolerated without any tumor lysis syndrome (TLS)

Dr.

The annual ASH Annual Conference is one of the largest and most comprehensive international academic conferences in the field of hematology in the world, bringing together the latest and most cutting-edge research and development progress in this field

APG-2575 was selected for the 2021 ASH annual meeting, and the two research summaries are as follows:

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R /R) Hematologic Malignancies (HMs)

Phase I clinical study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the new BCL-2 inhibitor lisaftoclax (APG-2575) in the treatment of hematological tumors (HMs)

Presentation format: poster presentation Abstract number: 3730 Session: 642.

Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL)

Phase Ib clinical study of lisaftoclax (APG-2575) as a single agent or in combination in the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL)

Presentation format: Poster presentation Abstract number: 1554 Session: 642.

The research summary of APG-1252 selected for the 2021 ASH Annual Meeting is as follows:

Antitumor Activity of Dual BCL-2/BCL-Xl Inhibitor Pelcitoclax (APG-1252) in Natural Killer/T-Cell Lymphoma (NK/TCL)

Anti-natural killer/T cell lymphoma (NK/TCL) activity of BCL-2/BCL-xL dual target inhibitor pelcitoclax (APG-1252)

Presentation format: Poster presentation Abstract number: 2062 Session: 203.

About Lisaftoclax (APG-2575)

APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under research by Ascent Pharmaceuticals.

APG-2575 has been carried out in the United States, China, Australia, Europe and other places around the world, including the treatment of chronic lymphocytic leukemia, acute myeloid leukemia, breast cancer, and other blood tumors and solid tumors clinical research

About Pelcitoclax (APG-1252)

APG-1252 is a new Bcl-2/Bcl-xL dual-target inhibitor independently developed by Yasheng Pharmaceutical, which can repair cell apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins

About Yasheng Pharmaceutical (6855.

Ascent Pharmaceuticals is an original innovative drug research and development company based in China and facing the world in the clinical development stage.

Ascent Pharmaceuticals has a self-constructed protein-protein interaction targeted drug design platform, and is at the forefront of new drug development in the apoptosis pathway in the world

Relying on strong R&D capabilities, Yasheng Pharmaceuticals has deployed intellectual property rights globally, and cooperated with leading biotechnology and pharmaceutical companies such as UNITY, MD Anderson, Mayo Medical Center, Dana-Farber Cancer Institute, Merck & Co.

Forward-looking statement

The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article

Source: Yasheng Pharmaceutical